LRP1B Mutation is Associated with Tumor Immune Microenvironment and Progression-free Survival in Lung Adenocarcinoma Treated with Immune Checkpoint Inhibitors

Overview

Journal Transl Lung Cancer Res

Date 2023 Apr 14

PMID 37057124

Authors

Ziyi He

Wei Feng

Yuxuan Wang

Liang Shi

Yuhui Gong

Yichao Shi

Shiyu Shen

Haitao Huang

Affiliations

Soon will be listed here.

Abstract

Background: Only a fraction of lung adenocarcinoma (LUAD) patients are eligible for immunotherapy. The identification of biomarkers for immunotherapy is crucial to improve patient outcomes. This study aims to systemically analyze mutation and its association with the tumor immune microenvironment (TIME) and immunotherapy.

Methods: A cohort of immune checkpoint inhibitors (ICIs)-treated LUAD patients was analyzed to assess the association of mutation with immunotherapy prognosis. Another cohort of LUAD patients with genetic and transcriptomic data was also obtained from The Cancer Genome Atlas (TCGA). By investigating the ICIs and the TCGA-LUAD cohorts, we compared the differences in mutation profiles, immunogenicity, TIME, and DNA damage repair (DDR) mutations between the -mutated and wild-type groups. Additionally, we performed multiplex immunohistochemistry (mIHC) to validate the differences in the tumor microenvironment.

Results: Our results revealed that mutation is associated with multiple immune-related pathways. Analysis of TIME indicated that LUAD patients with mutation expressed significant levels of genes involved in antigen presentation, cytotoxicity, chemokines, and pro-inflammatory mediators, whereas a few immune checkpoint genes were highly expressed in the -mutated group as well. Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) analysis indicated that -mutated LUAD patients had higher infiltration of active immune cells. Multiplex IHC analysis showed that -mutated LUAD patients had elevated programmed death ligand-1 (PD-L1) expression and immune cell infiltration. Patients with mutation had higher tumor mutation burden, neoantigens, as well as more mutated genes in the DDR-related pathways. Finally, -mutated LUAD patients showed a significant prolongation of progression-free survival (PFS) in the ICIs cohort and could be effectively predicted by our constructed nomogram.

Conclusions: Our study suggests that mutation is associated with higher immune cell infiltration and elevated immune gene expression in TIME and potentially serves as a prognostic biomarker for LUAD patients treated with ICIs.

Citing Articles

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer.

Eklund E, Svensson J, Naslund L, Yhr M, Sayin S, Wiel C J Exp Clin Cancer Res. 2025; 44(1):75.

PMID: 40011914 PMC: 11866712. DOI: 10.1186/s13046-025-03342-6.

B-cell signatures characterize the immune landscape and predict LUAD prognosis via the integration of scRNA-seq and bulk RNA-seq.

Xu K, Han D, Fan Z, Li Y, Liu S, Liao Y Sci Rep. 2025; 15(1):5453.

PMID: 39953119 PMC: 11828960. DOI: 10.1038/s41598-025-89213-8.

LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients.

Weng W, He S, Zhang G, Zhou X, Li K, Lai J Clinics (Sao Paulo). 2024; 79:100516.

PMID: 39532036 PMC: 11599987. DOI: 10.1016/j.clinsp.2024.100516.

Efficacy and challenges of anti-PD1 in MSI-H mCRC: a case report on concurrent infections and ir-AIHA.

Pei X, Zhao J, Luo R, Da L, Li E, Zhu H Front Oncol. 2024; 14:1407312.

PMID: 39193390 PMC: 11347344. DOI: 10.3389/fonc.2024.1407312.

The immune response-related genomic alterations in patients with malignant melanoma.

Li L, Xiang T, Li X Medicine (Baltimore). 2024; 103(17):e37966.

PMID: 38669390 PMC: 11049764. DOI: 10.1097/MD.0000000000037966.

References

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Akdis M, Aab A, Altunbulakli C, Azkur K, Costa R, Crameri R . Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016; 138(4):984-1010. DOI: 10.1016/j.jaci.2016.06.033. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Colaprico A, C Silva T, Olsen C, Garofano L, Cava C, Garolini D . TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015; 44(8):e71. PMC: 4856967. DOI: 10.1093/nar/gkv1507. View

Rimm D, Han G, Taube J, Yi E, Bridge J, Flieder D . A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017; 3(8):1051-1058. PMC: 5650234. DOI: 10.1001/jamaoncol.2017.0013. View

10.

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

11.

Chen H, Chong W, Wu Q, Yao Y, Mao M, Wang X . Association of Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Front Immunol. 2019; 10:1113. PMC: 6536574. DOI: 10.3389/fimmu.2019.01113. View

12.

Asmann Y, Parikh K, Bergsagel P, Dong H, Adjei A, Borad M . Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. NPJ Precis Oncol. 2021; 5(1):22. PMC: 7979755. DOI: 10.1038/s41698-021-00164-5. View

13.

Freitas J, Lopez J, Llorian C, Boroni M, Kos L . The immunosuppressive role of Edn3 overexpression in the melanoma microenvironment. Pigment Cell Melanoma Res. 2021; 34(6):1084-1093. DOI: 10.1111/pcmr.13002. View

14.

Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vallome G . Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers (Basel). 2020; 12(5). PMC: 7281184. DOI: 10.3390/cancers12051125. View

15.

Fridman W, Remark R, Goc J, Giraldo N, Becht E, Hammond S . The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol. 2014; 164(1):13-26. DOI: 10.1159/000362332. View

16.

He Y, Yu H, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R . LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017; 12(5):814-823. DOI: 10.1016/j.jtho.2017.01.019. View

17.

Liu C, Musco S, Lisitsina N, Forgacs E, Minna J, Lisitsyn N . LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 2000; 60(7):1961-7. View

18.

Tomlins S, Khazanov N, Bulen B, Hovelson D, Shreve M, Lamb L . Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Commun Med (Lond). 2023; 3(1):14. PMC: 9905474. DOI: 10.1038/s43856-023-00243-7. View

19.

Inoue H, Park J, Kiyotani K, Zewde M, Miyashita A, Jinnin M . Intratumoral expression levels of , , and along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology. 2016; 5(9):e1204507. PMC: 5048759. DOI: 10.1080/2162402X.2016.1204507. View

20.

Brown L, Tucker M, Sedhom R, Schwartz E, Zhu J, Kao C . mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J Immunother Cancer. 2021; 9(3). PMC: 7929846. DOI: 10.1136/jitc-2020-001792. View